A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).

Makoto Endo,Kazuhiro Tanaka,Yoshihiro Matsumoto,Hiroaki Hiraga,Shintaro Iwata,Satoshi Tsukushi,Munenori Watanuki,Toru Akiyama,Tsukasa Yonemoto,Robert Nakayama,Keisuke Ae,Hiroyuki Kawashima,Hiroyuki Tsuchiya,Hirohisa Katagiri,Akihito Nagano,Satoshi Takenaka,Tomoko Kataoka,Ryunosuke Machida,Haruhiko Fukuda,Toshifumi Ozaki

A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).

2021

TPS11580Background: Soft tissue sarcomas (STS) are a rare type of malignancy, which comprises of a variety of histologies. Chemotherapy is the standard treatment for patients with advanced STS. Dox...

Keywords:

Trabectedin
Oncology
Medicine
Chemotherapy
Internal medicine
Soft tissue
Soft tissue sarcoma
Malignancy
Eribulin
Standard treatment
Pazopanib

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations